OMER News and Press, Omeros Corporation From 10/22/20

Omeros (OMER) has announced final data from its pivotal trial for narsoplimab (OMS721) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), a frequently lethal complication of HSCT. Interim data from the study was reported in December ...

-- Webcast Scheduled for Today at 8:30am ET-- Omeros Corporation (Nasdaq: OMER) today announced final data from its pivotal trial for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), an often-lethal complication of stem-cell...

Omeros Corporation (Nasdaq: OMER) presented data from its OMS906 program yesterday at the 4 th Complement-based Drug Development Summit. OMS906 is the company’s lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3), the k...

-- Efficacy Results Surpass Those from Preliminary Analysis Previously Reported -- Omeros Corporation (Nasdaq: OMER) today announced that the final results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microa...

OMER share price has been depressed over continued uncertainty regarding sales of their primary revenue-driver. Recent completion of capital raise gives sufficient liquidity to realize upcoming milestones. Narsoplimab BLA is a potential value inflection point for OMER and transfor...

—OMIDRIA meets all objective criteria established by CMS— Omeros Corporation (Nasdaq: OMER) today provided an update on the status of reimbursement for its cataract surgery drug OMIDRIA ® (phenylephrine and ketorolac intraocular solution) 1%/0.3% ....

Omeros Corporation (Nasdaq: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the Cantor Virtual Global Healthcare Conference next week. The presentation is scheduled for Tuesday, September 15, 2020 at 11:20 a.m. EDT. The presenta...

- Omeros’ investigational agent narsoplimab discussed as a potentially highly effective therapy - Omeros Corporation (Nasdaq: OMER) today announced that the Demy-Colton Virtual Salon Series featured an expert discussion of developments in the treatment of severe COVID-19. The pane...

-- Paroxysmal Nocturnal Hemoglobinuria Slated as Initial Indication -- Omeros Corporation today announced that its Investigational New Drug Application (IND) to begin clinical trials with OMS906 has been cleared by the U.S. Food and Drug Administration (FDA). OMS906 is the company ...

The S&P 500 made new, all-time highs this week. Yet, many stocks are struggling. This is a red flag and harbinger of future weakness. Assured Guaranty (AGO), Omeros (OMER), Dynavax Technologies (DVAX), Flexion Therapeutics (FLXN), and Children's Place (PLCE) are five stocks downgraded by th...